AnaptysBio, an early-stage biotech developing antibodies for severe inflammatory conditions, raised $75 million by offering 5 million shares at $15, within the range of $14 to $16. It had previously filed to offer 4 million shares. AnaptysBio plans to list on the Nasdaq under the symbol ANAB. Credit Suisse and Stifel acted as lead managers on the deal.
